SEHK:6185Biotechs
CanSino Biologics (SEHK:6185) Reports Rising Sales And Revenue
CanSino Biologics (SEHK:6185) recently reported significant improvements in its financial performance, with sales and revenue both rising and a substantial reduction in net loss—a report that likely played a crucial role in the company's 53% price surge in the last quarter. The approval for commencing clinical trials of its polio vaccine and the authorization of a new pneumococcal vaccine may have added further optimism and investor confidence. While major U.S. stock markets also experienced...